Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy
نویسندگان
چکیده
منابع مشابه
Thrombotic microangiopathy during carfilzomib use: case series in Singapore
Carfilzomib is an irreversible proteasome inhibitor and is an effective treatment for multiple myeloma (MM). It received US Food and Drug Administration approval based on a single-arm multicenter trial of carfilzomib monotherapy in 266 patients with relapsed MM following at least two prior lines of treatment including bortezomib and immunomodulators. Safety analyses from four phase II carfilzom...
متن کاملHIV associated thrombotic microangiopathy.
Thrombotic microangiopathy (TMA) is a known complication of HIV infection. Endothelial cell injury appears to be the primary event causing platelet activation and deposition in the microvasculature. Direct cytopathic roles of HIV as well as other factors such as malignancy, drugs, and infectious agents have been implicated in the pathogenesis of HIV-TMA. Although the the majority of patients pr...
متن کاملPregnancy Associated Thrombotic Microangiopathy
The thrombotic microangiopathies (TMA) are a group of common microvascular occlusive disorders characterized by thrombocytopenia, microangiopathic hemolysis and multiorgan dysfunction. The pathological features are vascular damage manifested by arteriolar and capillary thrombosis with characteristic abnormalities in the endothelium and vessel wall. Pregnancy associated TMA is a life threatening...
متن کاملCancer-associated thrombotic microangiopathy
Cancer-associated thrombotic microangiopathy refers to a group of disorders characterised by microvascular thrombosis, thrombocytopenia, and ischaemic end-organ damage. Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura are the two major subtypes. It can be a manifestation of the malignancy itself or a complication of its therapy. The addition of several new drugs to the therap...
متن کاملBreast Cancer-Associated Thrombotic Microangiopathy.
BACKGROUND: Thrombotic microangiopathy (TMA) is defined as thrombocytopenia and microangiopathic hemolytic anemia. Cancer-associated TMA, a rare but fatal condition, seems an entity distinct from classical thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS). PATIENTS AND METHODS: All patients with breast cancer-associated TMA treated at our institution between 2003 and 20...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Medical Case Reports
سال: 2019
ISSN: 2374-2151
DOI: 10.12691/ajmcr-7-10-5